Deerfield Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Deerfield Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,519,718	Closed	-$71.3M	–	105
2019 Q4	$71.3M	Sell	1,519,718 -208,301	-12%	-$9.21M	2.28%	12
2019 Q3	$40.9M	Buy	1,728,019 +15,019	+0.9%	+$445K	1.67%	16
2019 Q2	$51.5M	Buy	1,713,000 +211,000	+14%	+$4.83M	1.85%	13
2019 Q1	$33.6M	Hold	1,502,000	–	–	1.29%	26
2018 Q4	$27.3M	Buy	1,502,000 +1,119,300	+292%	+$17.6M	1.09%	35
2018 Q3	$6.92M	Hold	382,700	–	–	0.25%	81
2018 Q2	$3.81M	Hold	382,700	–	–	0.13%	101
2018 Q1	$2.03M	Buy	382,700 +303,550	+384%	+$2.17M	0.07%	112
2017 Q4	$673K	Sell	79,150 -23,000	-23%	-$283K	0.03%	98
2017 Q3	$1.49M	Buy	102,150 +19,557	+24%	+$296K	0.07%	91
2017 Q2	$1.55M	Sell	82,593 -95,237	-54%	-$2.15M	0.08%	82
2017 Q1	$3.79M	Sell	177,830 -145,800	-45%	-$2.79M	0.15%	90
2016 Q4	$4.92M	Buy	+323,630	New	+$4.4M	0.2%	77

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management's RARX Position: Q1 2020 in Review

Deerfield Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2020, closing a stake of 1,519,718 shares — an estimated $71.3M sold.

Deerfield Management first reported a position in RARX in Q4 2016 and held it in 13 quarters. The position peaked at $71.3M in Q4 2019. 144 funds tracked by Wall St. Rank hold RARX as of Q1 2020.

Deerfield Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Deerfield Management sold 1,519,718 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $71.3M.
Deerfield Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 13 quarters.
Deerfield Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $71.3M in Q4 2019.
144 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Deerfield Management's 13F filing for Q1 2020, filed 15 May 2020.